Advances in Urology

Research Article

Extended Use of The Spanner® Temporary Prostatic Stent in Catheter-Dependent Men with Comorbidities

Table 3

Subgroup analyses.


	Age group		Catheter type		Comorbidities				Overall study data
	Age	Age	Foley	CIC	MI	CHF	DM	PVD
	50–77	78–97	Foley	CIC	MI	CHF	DM	PVD

Number and % of subjects in subgroup
n	50 (46.7%)	57 (53.3%)	63 (58.9%)	40 (37.4%)	40 (37.4%)	34 (31.8%)	28 (26.2%)	25 (23.4%)	107
Met primary endpoint-adequate bladder drainage
n/N	36/50	44/57	47/63	30/40	28/40	27/34	23/28	18/25	79/107
(%)	72.0%	77.2%	74.6%	75.0%	70.0%	79.4%	82.1%	72.0%	73.8%
Contracted SUTI
n/N	3/50	1/57	3/63	1/40	3/40	0/34	2/28	0/25	4/107
(%)	6.0%	1.7%	4.7%	2.5%	7.5%	0.0%	7.1%	0.0%	3.7%

Subgroup analysis data for the two primary endpoint treatment effects: (a) adequate bladder drainage, and (b) SUTI. Subgroup analysis by (i) age (segregated by median age), (ii) catheterization use at enrollment (foley; clean intermittent catheterization (CIC)), and (iii) most prevalent comorbidities at enrollment (myocardial infarction (MI), congestive heart disease (CHF), diabetes mellitus [DM], peripheral vascular disease (PVD)).